查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1355209

数位病理市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品类型、按应用、最终用户、地区和竞争细分

Digital Pathology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product Type, By Application, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球数位病理学市场估值为 9.3 亿美元，预计到 2028 年预测期内将强劲增长，复合年增长率为 10.19%。数位病理学是一个专注于从数位化标本载玻片中提取资料的专业领域。透过利用基于电脑的技术和虚拟显微镜，数位病理学能够获取基于影像的资讯。这种创新方法显着提高了全球病理实验室的效率、工作流程和收入。透过将载玻片转换为数位对应物，使用者可以在电脑显示器上轻鬆管理、分享、检视和分析它们。数位病理学在多个领域都有应用，包括原发性疾病诊断、诊断决策支援、术中诊断、诊断咨询、住院医师和医疗培训、同行评审、手动和半定量免疫组织化学(IHC) 审查以及临床研究。它的实施提高了实验室效率并加快了诊断结果。随着教育部门、药物开发、组织研究和疾病诊断的持续支持，数位病理学作为医疗保健领域一项重要且经过验证的技术正在迅速获得认可。

主要市场驱动因素

提高实验室效率

市场概况
预测期 2024-2028
2022 年市场规模 9.3亿美元
2028 年市场规模 16.5亿美元
2023-2028 年复合年增长率 10.19%
成长最快的细分市场 疾病诊断
最大的市场 北美洲

数位病理学透过减少週转时间、降低成本并向具有主题专业知识的用户提供全面的详细资讯来提高效率。提高实验室结果至关重要，因为医生和患者严重依赖实验室结果进行疾病诊断和治疗。数位病理学允许快速远端存取病理影像，从而实现医疗保健专业人员之间更快的协作。病理学家和专家可以不受物理距离的限制审查病例并提供咨询，从而可能更快地做出诊断和治疗决策。传统病理学涉及准备和运输物理载玻片，这可能既耗时又昂贵。借助数位病理学，可以减少与玻片製作、运输、储存和检索相关的费用。对准确、高效、及时的实验室结果的需求不断增长，推动了数位病理市场的成长。

科技的快速进步

数位病理系统的快速进步预计将推动市场成长。数位成像、电脑化、机器人光学显微镜和光纤通讯都在这一扩张中发挥重要作用。全玻片成像是一种比传统光学显微镜具有众多优势的技术，预计将对市场产生正面影响。此外，微阵列和各种预测模型（例如混合模型和 API 演算法）的发展预计将进一步加速数位影像分析的市场成长。人们越来越喜欢电脑辅助诊断，它整合了影像处理、物理、数学和计算演算法，有助于有效的疾病检测，并能够评估感兴趣的解剖结构、疾病进展和风险评估。

人工智慧在医疗保健领域的应用不断增加

人工智慧在医疗保健中的应用不断增加，人们越来越关注透过将人工智慧整合到包括病理诊断在内的不同医疗保健服务中来提高患者护理品质。 AI演算法可以快速且准确地分析大量病理影像。它们可以帮助病理学家检测异常、识别模式并提供更精确的诊断，最终导致更快的治疗决策并改善患者的治疗结果。人工智慧可以透过提供客观、一致的分析来帮助减少病理诊断中的人为错误和变异性。这对于可能错过细微特征的复杂情况尤其有价值。透过将患者资料与人工智慧见解相结合，病理学家和临床医生可以为个别患者量身定制治疗计划，优化治疗方法并最大程度地减少不必要的干预。因此，人工智慧 (AI) 有助于简化初级保健流程和自动化，使医生能够优先考虑病情更危重的患者。此外，医疗保健产业的人工智慧解决方案正在逐步采用更以人为本的方法。

癌症盛行率增加

根据世界卫生组织的数据，2018 年全球有 960 万人死亡，新增 1,810 万癌症病例，这是史无前例的。全球人口老化和久坐生活方式的加剧导致癌症病例数量不断增加。该联合国组织预测，到2050年，老年人数量将达到近21亿。使用动物模型和临床试验进行的临床前研究在确定药物的安全性和有效性方面发挥着至关重要的作用。数位病理学具有多种优势，例如降低错误风险、储存药物资料、将资料整合到电子健康记录 (EHRS) 以及评估患者对特定药物的反应。由于对药物开发和药物发现研发的日益关注，全球数位病理学产业正在经历成长，导致临床和临床前试验的增加。对癌症等慢性病更快诊断工具的需求以及提高工作流程生产力的需求是驱动因素。此外，越来越多的老年人口更容易患慢性病，预计将进一步增加对先进技术诊断程序的需求。

主要市场挑战

数位病理学的高成本

数位病理学的高成本以及新兴和不发达国家的低采用率阻碍了市场的成长。 Augmenting 透过提供具有整合数位病理软体应用程式的模组化硬体平台来应对这项挑战，有助于降低成本。实施数位病理系统需要在扫描器、储存基础设施和软体解决方案方面进行大量前期投资。与载玻片数位化、维护数位檔案和培训人员相关的费用可能很大，特别是对于预算有限的小型实验室或医疗机构。此外，将数位病理学整合到现有实验室工作流程以及 IT 支援和基础设施升级的需求可能会给一些组织带来挑战。

监管和标准化挑战

数位病理学的采用受到不同地区不同监管要求和标准的影响。数位病理系统和软体的验证和监管批准可能是一个复杂且耗时的过程。此外，在数位病理影像的传输和储存过程中，解决与资料隐私、安全性和遵守病患保密法规相关的挑战至关重要。在数位病理解决方案用于临床诊断之前，通常需要经过严格的验证过程，以证明其准确性、可靠性和安全性。不同地区的监管机构批准这些技术的标准可能不同。病患资料安全和隐私在医疗保健中至关重要。数位病理系统必须遵守严格的资料保护法规，例如美国的健康保险流通和责任法案（HIPAA）和欧盟的一般资料保护规范（GDPR）。

主要市场趋势

远距病理学和远距会诊

远距病理学的日益普及使得远距诊断和咨询成为可能，使病理学家能够协作并提供专家意见，而不受地理限制。远距病理学在 COVID-19 大流行期间获得了显着的重视，因为它促进了远距工作并最大限度地降低了病理学家的暴露风险。例如，病理学家可以与同事远端审查和讨论病例，参与多学科肿瘤委员会，或为服务不足的地区或面临病理学专业知识短缺的地区提供咨询。人们越来越倾向于整合影像处理、物理、数学和计算演算法的电脑辅助诊断，有助于有效的疾病检测。它还有助于评估感兴趣的解剖结构、量化疾病进展和风险评估，从而刺激市场成长。值得注意的是，奥林巴斯等公司提供了一系列用于远端幻灯片共享和影像处理的工具，有助于预计未来几年的市场扩张。 2020 年 4 月，徕卡生物系统公司的 Aperio AT2 DX 扫描仪和 Aperio WebViewer 获得 FDA 批准，从而在大流行期间实现远端诊断。此外，在这次紧急情况下，飞利浦的 IntelliSite 病理学解决方案还获得了 FDA 的批准，进一步支持远端诊断。

人工智慧和机器学习的分析集成

将人工智慧（AI）和机器学习演算法纳入数位病理平台是一个重要的新兴趋势。人工智慧有能力协助病理学家完成各种任务，包括自动组织识别、异常检测、生物标记量化和疾病结果预测。这些技术在提高病理诊断的效率、准确性和可重复性方面具有巨大潜力。例如，人工智慧演算法可以帮助癌细胞的自动检测和分类，以及组织病理学影像中特定特征的识别。

细分市场洞察

应用洞察

由于慢性病盛行率不断上升，预计疾病诊断领域在预测期内将显着增长。数位病理学涵盖一系列疾病诊断技术，包括实验室管理系统、数位听写、仪表板和工作流程控制、数位影像分析、电子标本标籤和监测以及概要报告工具。製造商目前专注于开发新颖且快速的诊断技术。数位科技的整合增强了诊断过程的每个阶段，并促进部门内部和部门之间的无缝资讯交换。

最终使用者见解

製药和生物技术公司代表了最终用户全球数位病理学需求的最大部分。该细分市场的巨大份额和快速增长速度可归因于多种因素。其中包括在药物发现研究和药物毒理学研究中越来越多地利用数位病理学。此外，生物技术公司利用数位病理学来开发生物样本库、生物製药试验、分子测定和个人化医疗。

区域洞察

由于持续的研发投资、政府支援技术先进系统的倡议、数位影像的日益普及以及知名企业的参与，北美占据了最大的市场份额。在北美，在专注于数位病理学研究和影像分析增强​​工具开发的公司的推动下，美国成为市场领导者。数位病理学在疾病诊断中的加速应用，加上美国有利的报销政策，预计将推动该地区的成长并提高癌症诊断的标准。数位病理学在教育和培训中的日益普及，以及人工智慧与数位病理系统的集成，是推动区域市场成长的关键因素。

对数位病理学项目、教育和培训项目的支持不断增加，推动了欧洲市场的成长。癌症发病率上升、英国越来越多地采用数位病理学解决方案以及德国会议数量不断增加等因素也促成了这一增长。数位病理学涉及扫描玻片以产生虚拟影像，该影像与临床资料一起为病理学家提供癌症患者的综合影像。这使得额外的诊断程序成为可能，包括影像分析研究，这是传统玻片无法实现的。英国数位病理学的采用率很高，预计未来几年将进一步扩大。此外，英国的病理学家表示需要数位病理学解决方案的指导、培训和教育。随着英国癌症发病率的增加，该国的数位病理市场预计将在预测期内扩大。

主要市场参与者

  • 3DHISTECH
  • 科里斯塔
  • 艾福利亚科技有限公司
  • 阿科亚生物科学公司
  • 光扫描
  • 格伦科软体
  • QProscia公司
  • 坎特龙系统公司
  • 微扫描技术公司

报告范围：

数位病理学市场，按产品类型：

  • 扫描仪
  • 软体
  • 储存和通讯系统

数位病理学市场，按应用：

  • 疾病诊断
  • 远距会诊
  • 药物发现
  • 培训与教育

数位病理学市场，按最终用户划分：

  • 製药与生物技术公司
  • 医院和诊所
  • 学术机构与研究实验室

数位病理学市场，按地区：

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 法国
    • 英国
    • 义大利
    • 德国
    • 西班牙
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特
    • 土耳其
    • 埃及

竞争格局

公司概况：全球数位病理市场主要公司的详细分析。

可用的客製化：

全球数位病理学市场报告以及给定的市场资料，技术科学研究根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球数位病理市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品类型（扫描器、软体以及储存和通讯系统）
    • 按应用（疾病诊断、远距咨询、药物发现、培训和教育）
    • 按最终用户（製药和生物技术公司、医院和诊所、学术机构和研究实验室）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美数位病理市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲数位病理市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区数位病理市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲数位病理市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲数位病理市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 按应用
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非数位病理学
    • 沙乌地阿拉伯数位病理学
    • 阿联酋数位病理学

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球数位病理学市场：SWOT 分析

第14章：竞争格局

  • 商业概览
  • 应用程式产品
  • 最近的发展
  • 主要人员
  • SWOT分析
    • 3DHISTECH
    • Corista
    • Aiforia Technologies Oy
    • Akoya Biosciences
    • OptraSCAN
    • Glencoe Software
    • QProscia Inc
    • Kanteron Systems
    • Mikroscan Technologies

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 1615

Global Digital Pathology Market was valued at USD 0.93 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 10.19% through 2028. Digital pathology is a specialized field that focuses on extracting data from digitized specimen slides. By utilizing computer-based technology and virtual microscopy, digital pathology enables the acquisition of image-based information. This innovative approach has significantly enhanced the efficiency, workflow, and revenue of pathology labs worldwide. Through the conversion of glass slides into digital counterparts, users can effortlessly manage, share, view, and analyze them on a computer monitor. Digital pathology finds applications in various areas, including primary disease diagnosis, diagnostic decision support, intraoperative diagnosis, diagnostic consultation, resident and medical training, peer review, manual and semi-quantitative immunohistochemistry (IHC) review, and clinical research. Its implementation has led to improved laboratory efficiency and faster diagnostic results. With growing support from the education sector, drug development, tissue-based research, and disease diagnosis, digital pathology is rapidly gaining recognition as an essential and proven technology in the healthcare sector.

Key Market Drivers

Enhanced Lab Efficiency

Market Overview
Forecast Period2024-2028
Market Size 2022USD 0.93 Billion
Market Size 2028USD 1.65 Billion
CAGR 2023-202810.19%
Fastest Growing SegmentDisease Diagnosis
Largest MarketNorth America

Digital pathology enhances efficiency by reducing turnaround time, lowering costs, and delivering comprehensive details to users with subject-matter expertise. Enhancing laboratory results is crucial as physicians and patients rely heavily on them for disease diagnosis and treatment. Digital pathology allows for rapid and remote access to pathology images, enabling faster collaboration among healthcare professionals. Pathologists and experts can review cases and provide consultations without the constraints of physical distance, potentially leading to quicker diagnosis and treatment decisions. Traditional pathology involves preparing and transporting physical slides, which can be time-consuming and costly. With digital pathology, there is a reduction in expenses related to slide production, shipping, storage, and retrieval. The increasing demand for accurate, efficient, and prompt laboratory results is fueling the growth of the digital pathology market.

Rapid Technological Advancements

Rapid advancements in digital pathology systems are anticipated to fuel market growth. Digital imaging, computerization, robotic light microscopy, and fiber optic communications all play a significant role in this expansion. Whole slide imaging, a technique with numerous advantages over conventional light microscopes, is projected to positively impact the market. Moreover, the development of microarrays and a wide range of predictive models, such as hybrid models and API algorithms, is anticipated to further accelerate market growth for digital image analysis. The increasing preference for computer-aided diagnosis, which integrates image processing, physics, mathematics, and computational algorithms, facilitates efficient disease detection and enables the assessment of anatomical structures of interest, disease progression, and risk assessment.

Rising Use of AI In Healthcare

The utilization of AI in healthcare is on the rise, with a growing focus on enhancing patient care quality through the integration of AI in different healthcare services, including pathological diagnosis. AI algorithms can analyze large volumes of pathology images quickly and accurately. They can assist pathologists in detecting abnormalities, identifying patterns, and providing more precise diagnoses, ultimately leading to faster treatment decisions and improved patient outcomes. AI can help mitigate human errors and variability in pathological diagnosis by providing objective and consistent analyses. This is especially valuable for complex cases where subtle features might be missed. By integrating patient data with AI insights, pathologists and clinicians can tailor treatment plans to individual patients, optimizing therapeutic approaches and minimizing unnecessary interventions. Consequently, artificial intelligence (AI) facilitates streamlined primary care processes and automation, enabling physicians to prioritize patients with more critical conditions. Additionally, AI solutions in the healthcare industry are progressively adopting a more human-centered approach.

Increasing Prevalence of Cancer

According to the World Health Organization, there were an unprecedented 9.6 million deaths and 18.1 million new cancer cases recorded worldwide in 2018. The increasing aging population and sedentary lifestyles globally are contributing to the rising number of cancer cases. The UN organization predicts that the number of older persons will reach nearly 2.1 billion by 2050. Preclinical research using animal models and clinical trials plays a vital role in determining the safety and efficacy of drugs. Digital pathology offers multiple benefits, such as reducing the risk of error, storing drug data, integrating data into electronic health records (EHRS), and assessing patient reactions to specific medications. The global digital pathology industry is experiencing growth due to the increasing focus on drug development and drug discovery research and development, leading to a rise in clinical and preclinical trials. The demand for faster diagnostic tools for chronic diseases like cancer and the need to enhance workflow productivity are driving factors. Additionally, the growing geriatric population, which is more susceptible to chronic conditions, is expected to further increase the demand for advanced technical diagnostic procedures.

Key Market Challenges

High Cost of Digital Pathology

The high cost of digital pathology and the low adoption rate in emerging and underdeveloped countries present obstacles to the market's growth. Augmenting addresses this challenge by offering a modular hardware platform with integrated digital pathology software applications, helping to keep costs low. Implementing digital pathology systems requires significant upfront investment in scanners, storage infrastructure, and software solutions. The expenses associated with digitizing slides, maintaining digital archives, and training personnel can be substantial, especially for small laboratories or healthcare facilities with limited budgets. Furthermore, integrating digital pathology into existing laboratory workflows and the need for IT support and infrastructure upgrades can pose challenges for some organizations.

Regulatory and Standardization Challenges

The adoption of digital pathology is influenced by regulatory requirements and standards that vary across different regions. The validation and regulatory approval of digital pathology systems and software can be a complex and time-consuming process. Additionally, addressing challenges related to data privacy, security, and compliance with patient confidentiality regulations during the transmission and storage of digital pathology images is crucial. Before digital pathology solutions can be used for clinical diagnosis, they often need to undergo rigorous validation processes to demonstrate their accuracy, reliability, and safety. Regulatory authorities in different regions may have varying criteria for approving these technologies. Patient data security and privacy are paramount in healthcare. Digital pathology systems must adhere to strict data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in the European Union.

Key Market Trends

Telepathology and Remote Consultation

The increasing adoption of telepathology enables remote diagnosis and consultation, allowing pathologists to collaborate and provide expert opinions without being limited by geographical constraints. Telepathology has gained significant prominence during the COVID-19 pandemic, as it facilitates remote working and minimizes the risk of exposure for pathologists. For instance, pathologists can remotely review and discuss cases with colleagues, participate in multidisciplinary tumor boards, or offer consultations to underserved areas or regions facing a shortage of pathology expertise. The increasing preference for computer-aided diagnosis, integrating image processing, physics, mathematics, and computing algorithms, facilitates efficient disease detection. It also assists in evaluating anatomic structures of interest, quantifying disease progression, and risk assessment, thereby stimulating market growth. Notably, companies like Olympus offer a range of tools for remote slide sharing and image processing, contributing to anticipated market expansion in the upcoming years. In April 2020, Leica Biosystems obtained FDA approval for the Aperio AT2 DX Scanner and Aperio WebViewer, enabling remote diagnosis during the pandemic. Additionally, during this emergency, Phillips also received FDA approval for its IntelliSite Pathology Solution, further supporting remote diagnosis.

Analytics Integration of Artificial Intelligence and Machine Learning

The incorporation of Artificial Intelligence (AI) and machine learning algorithms into digital pathology platforms is a significant and emerging trend. AI has the capability to assist pathologists in various tasks, including automated tissue recognition, anomaly detection, biomarker quantification, and disease outcome prediction. These technologies hold great potential in enhancing efficiency, accuracy, and reproducibility in pathology diagnosis. For example, AI algorithms can aid in the automated detection and classification of cancer cells, as well as the identification of specific features in histopathological images.

Segmental Insights

Application Insights

The disease diagnostic segment is anticipated to witness significant growth during the forecast period due to the increasing prevalence of chronic diseases. Digital pathology encompasses a range of technologies for disease diagnosis, including laboratory management systems, digital dictation, dashboards and workflow control, digital image analysis, electronic specimen labeling and monitoring, and synoptic reporting tools. Manufacturers are currently focused on the development of novel and rapid diagnostic techniques. The integration of digital technology enhances every phase of the diagnostic process and facilitates seamless information exchange within and between departments.

End User Insights

The pharmaceutical and biotechnology companies represent the largest portion of global digital pathology demand by end-users. The significant share and rapid growth rate of this segment can be attributed to various factors. These include the increasing utilization of digital pathology in drug discovery studies and drug toxicology research. Additionally, biotechnology corporations leverage digital pathology for the development of biobanking, biopharmaceutical trials, molecular assays, and personalized medicine.

Regional Insights

North America holds the largest market share attributed to continuous R&D investments, government initiatives supporting technologically advanced systems, growing adoption of digital imaging, and the involvement of prominent players. In North America, the United States emerges as the market leader, driven by companies focusing on digital pathology research and the development of enhanced tools for image analysis. The accelerated use of digital pathology for disease diagnosis, coupled with favorable reimbursement policies in the U.S., is expected to drive regional growth and enhance the standard of cancer diagnosis. The increasing implementation of digital pathology in education and training, along with the integration of AI into digital pathology systems, are key factors propelling regional market growth.

The growth of the European market is fueled by increasing support for digital pathology projects, education, and training programs. Factors such as the rising incidence of cancer, the growing adoption of digital pathology solutions in the United Kingdom, and the increasing number of conferences in Germany also contribute to this growth. Digital pathology involves scanning glass slides to generate virtual images, which, along with clinical data, provide an integrated picture of cancer patients for pathologists. This enables additional diagnostic procedures, including image analysis studies, which are not possible with conventional glass slides. The United Kingdom shows a high adoption rate of digital pathology, with further expansion expected in the coming years. Moreover, pathologists in the United Kingdom express a need for guidance, training, and education on digital pathology solutions. With the increasing incidence of cancer in the United Kingdom, the digital pathology market in the country is projected to expand during the forecast period.

Key Market Players

  • 3DHISTECH
  • Corista
  • Aiforia Technologies Oy
  • Akoya Biosciences
  • OptraSCAN
  • Glencoe Software
  • QProscia Inc
  • Kanteron Systems
  • Mikroscan Technologies

Report Scope:

In this report, the Global Digital Pathology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Digital Pathology Market, By Product Type:

  • Scanners
  • Software
  • Storage & Communication Systems

Digital Pathology Market, By Application:

  • Disease Diagnosis
  • Teleconsultation
  • Drug Discovery
  • Training & Education

Digital Pathology Market, By End User:

  • Pharmaceutical & Biotechnology Companies
  • Hospitals and Clinics
  • Academic Institutes & Research Laboratories

Digital Pathology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Digital Pathology Market.

Available Customizations:

Global Digital Pathology market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Digital Pathology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Scanners, Software, and Storage & Communication Systems)
    • 5.2.2. By Application (Disease Diagnosis, Teleconsultation, Drug Discovery, Training & Education)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Hospitals and Clinics, Academic Institutes & Research Laboratories)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. North America Digital Pathology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Digital Pathology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Digital Pathology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Digital Pathology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Digital Pathology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Digital Pathology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Digital Pathology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Digital Pathology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Digital Pathology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Digital Pathology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Digital Pathology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Digital Pathology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Digital Pathology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Digital Pathology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Digital Pathology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Digital Pathology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Digital Pathology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Digital Pathology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Digital Pathology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Digital Pathology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Digital Pathology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Digital Pathology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Digital Pathology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Digital Pathology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Digital Pathology Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Application Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. 3DHISTECH
    • 14.5.2. Corista
    • 14.5.3. Aiforia Technologies Oy
    • 14.5.4. Akoya Biosciences
    • 14.5.5. OptraSCAN
    • 14.5.6. Glencoe Software
    • 14.5.7. QProscia Inc
    • 14.5.8. Kanteron Systems
    • 14.5.9. Mikroscan Technologies

15. Strategic Recommendations

16. About Us & Disclaimer